RE: Scenario15 Feb 2022 08:44
AS purposely tanking the SP for IIs is as much a conspiracy theory as the idea that he will put out a surprise placing when he's said there is runway till H2 2023. He has often not told the whole truth, for various reasons including NDA / NHS protocol, but the idea that he already knows the trials aren't going well would be barefaced lying. As such, why would he raise at any point before the P1 results can be made public midyear at the earliest?
I think two things are clear. LFT has been sabotaged by the DHSC and then by AS, with the company valuation taking a huge hit from those folks exiting since the announcement that AS eloquently put out: "um, err, no" to paraphrase. Secondly that the whole sector is in a rout. The Fed are tightening and biotech are super risky, the market believes COVID testing is winding up, and war fears are dropping all indices at the same time. This has compounded into a remarkable collapse in valuation driven largely by sentiment, but yes the fundamentals of half the business proposal have been completely gutted, there's no denying it. Valuation is now riding almost exclusively on one early stage biotech clinical trial, which are known to be very safe investments in this volatile time. I am shocked, as I guess everyone else is, how fast and deep this crash has gone - I increased my holding substantially at 95 twelve days ago, and I've seen my paper loss over triple, coming close to quadruple, in that time.